Lille, France-based Genfit SA generally is seen as the second-place player in the non-alcoholic steatohepatitis (NASH) space, behind presumed leader Intercept Pharmaceuticals Inc., but some market watchers don’t even rank the firm that highly because the Phase II study for its candidate elafibranor failed until the results were measured against a revised definition of NASH resolution.
Newly promoted CEO Pascal Prigent – a commercial-side veteran of Eli Lilly & Co. and GlaxoSmithKline PLC –...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
